BARDA Awards SCYNEXIS Up to $214M Non-Dilutive Funding for SCY-247 Antifungal
SCYX sits 83% above its 52-week low of $3.53 on light trading volume (0.2× avg).
Summary
SCYNEXIS secured a BARDA contract worth up to $214 million in non-dilutive funding to advance SCY-247, its second-generation antifungal, through NDA submission for two indications. The initial base period provides $18.5 million to move oral and IV formulations into a Phase 2 trial for invasive candidiasis. This is a major validation from a government agency and significantly de-risks the SCY-247 program without shareholder dilution. The company's cash runway into 2029 remains unchanged, and SCY-770 development continues as planned. The contract may extend up to 10 years, providing long-term funding visibility.
Updates
· SEC 8-K — The 8-K states the BARDA contract was entered into on September 25, 2026, and includes contract number 75A50126C00007.
At the time of this announcement, SCYX was trading at $6.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.7M. The 52-week trading range was $3.53 to $9.12. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.